Format

Send to

Choose Destination
J Biopharm Stat. 2012;22(1):72-92. doi: 10.1080/10543406.2010.504906.

Genomic biomarkers for a binary clinical outcome in early drug development microarray experiments.

Author information

1
Johnson & Johnson, PRD, Beerse, Belgium. svsande1@its.jnj.com

Abstract

In this article, we discuss methods to select three different types of genes (treatment related, response related, or both) and investigate whether they can serve as biomarkers for a binary outcome variable. We consider an extension of the joint model introduced by Lin et al. (2010) and Tilahun et al. (2010) for a continuous response. As the model has certain drawbacks in a binary setting, we also present a way to use classical selection methods to identify subgroups of genes, which are treatment and/or response related. We evaluate their potential to serve as biomarkers by applying DLDA to predict the response level.

PMID:
22204528
DOI:
10.1080/10543406.2010.504906
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center